Awaiting development: Guidance and quality standards

Showing 41 to 50 of 332

Guidance and quality standards awaiting development
Title	Type
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]	Technology appraisal guidance
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis [TSID10334]	Technology appraisal guidance
Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]	Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991]	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]	Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance